Ramos et al. [20] employed CD19-CAR3 T cells in treating 16 individuals with relapsed or refractory non-Hodgkin’s lymphoma, revealing enhanced expansion and prolonged survival compared to CD19-CAR2 T cells. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.